临床试验进展 - 公司正在进行DA-1241的2a期临床试验,用于治疗代谢紊乱相关的脂肪肝[105][106] - 公司正在进行DA-1726的1期临床试验,用于治疗肥胖[108][115] - 公司完成2a期DA-1241临床试验第二部分的患者入组[114] - 公司完成1期DA-1726临床试验第一部分的患者入组[110] - 公司完成1期DA-1726临床试验第二部分的首例患者给药[115] - 公司完成1期DA-1726临床试验第一部分的患者入组[119] - 公司完成2a期DA-1241临床试验第一部分的患者入组[120] 合作与人才引进 - 公司与Dong-A和ImmunoForge合作,开发DA-1726的长效缓释制剂[111] - 公司与MTHERA签订独家许可协议,授权其开发和商业化NB-01用于治疗糖尿病性神经痛[112] - 公司聘请Chris Fang博士担任首席医学顾问[113] 财务情况 - 公司总营业费用和经营亏损在2024年6月30日结束的六个月期间为1700万美元,较2023年6月30日结束的六个月期间增加1060万美元,增幅为168.2%[134] - 研发费用在2024年6月30日结束的六个月期间为1300万美元,较2023年6月30日结束的六个月期间增加1000万美元,增幅为332.5%[135] - 一般及行政费用在2024年6月30日结束的六个月期间为400万美元,较2023年6月30日结束的六个月期间增加70万美元,增幅为19.9%[136] - 其他收益在2024年6月30日结束的六个月期间为20万美元,较2023年6月30日结束的六个月期间减少280万美元,降幅为93.4%[137] - 公司在2024年6月30日结束的六个月期间的净亏损为1680万美元,每股基本和稀释亏损为3.19美元,而2023年6月30日结束的六个月期间的净亏损为333.8万美元,每股基本和稀释亏损为0.66美元[139] - 公司预计将继续在可预见的未来产生净亏损和经营活动的负现金流[141] - 公司相信现有现金将足以为其运营提供资金直到2025年第二季度[141] - 公司计划通过发行股票、债务融资或其他方式筹集资金以维持运营[142] - 2024年6月公司完成了一项注册直接发行和一项私募配售,共获得2000万美元的总收益[144][145] - 公司2024年6月30日结束的六个月期间的经营活动净现金流出为1370万美元[148]

财务状况 - 完成了高达7000万美元的融资,其中包括2000万美元的预付款和在临床里程碑期权全部行使后可获得5000万美元的总收益[2][3] - 截至第二季度末拥有2790万美元现金,预计可为公司提供资金支持,直到2025年第二季度[3] - 截至2024年6月30日，公司现金余额为2793.4万美元[32] - 2024年上半年研发费用为1297.8万美元，管理费用为398.7万美元[33] - 2024年上半年净亏损为1676.7万美元[33] - 截至2024年6月30日，公司发行在外的普通股为822.1万股[32] - 2024年第二季度每股亏损为1.85美元[33] - 2024年上半年每股亏损为3.19美元[33] 药物研发进展 - 在前期临床模型中,DA-1726展现出优于其他同类药物的减重、保持瘦体质量和降脂效果,以及优于tirzepatide的降糖效果[4] - 已完成DA-1726第1阶段单剂量递增试验的入组,预计在2024年第三季度公布顶线数据,并在2025年第一季度公布第2阶段多剂量递增试验的顶线数据[5] - 计划开展DA-1726第1阶段第3部分试验,探索在24周时的总体减重、最大可耐受剂量和饮食变化,预计2026年中期公布中期数据,2026年下半年公布顶线数据[6] - 与东亚ST和ImmunoForge签订联合研究协议,开发DA-1726的长效每月一次给药制剂[7] - DA-1241第2a期试验第2部分正在进行中,预计2024年第四季度公布顶线数据[8] - 公司正在开发DA-1726用于治疗肥胖症，开发DA-1241用于治疗代谢紊乱相关脂肪肝[28] - DA-1726是一种新型的胰高血糖素样肽-1受体(GLP1R)和胰高血糖素受体(GCGR)双激动剂[28] - DA-1241是一种新型的G蛋白偶联受体119(GPR119)激动剂，在临床前研究中显示了对肝脏炎症、脂质代谢、体重减轻和葡萄糖代谢的积极影响[28] 合作协议 - 与东亚ST和ImmunoForge签订联合研究协议,开发DA-1726的长效每月一次给药制剂[7] - 公司与Dong-A ST Co. Ltd.签署了许可协议[29]

Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based Warrants$27.9 Million in Cash at End of Second Quarter is Expected to Fund the Company Though Multiple Value-Creating Milestones, Into the Second Quarter of 2025. Assuming Positive Results From the DA-1726 Phase 1 MAD Study, the Company Anticipates That the Series A Warrants From the June Financing Could be Exercised ...

No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2Top Line Data Readout from SAD Part 1 Expected in the Third Quarter of 2024, and from the MAD Part 2 in the First Quarter of 2025CAMBRIDGE, Mass., Aug. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion ...

Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Times CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has signed a joint research agreement, together with Dong-A ST Co. Ltd. and ImmunoForge, to develop a long-acting, once-monthly, formulation of DA-1726, a novel, dual oxyntomoduli ...

CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the signing of an exclusive license agreement, providing MThera Pharma Co., Ltd. (MTHERA) with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in t ...

CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview at the Emerging Growth Conference on Thursday, July 18, 2024 at 10:50 am ET.During the virtual presentation, management will provide an update on the clinical development ...

Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Ascending Dose Part 2 in the First Quarter of 2025 Planned Part 3 Will Assess Total Weight Loss at 24 Weeks, Exploring Maximum Titratable Dose and Dietary Changes; Interim Data Readout Expected Mid-2026 with Top-Line Data in the Second Half of 2026 Recent Financing of up to $70 million Will Fund the Ongoing Clinical Development of DA-1726 CAMBRIDGE, Mass., June 26, 2024 /PRNewswire/ -- Ne ...

$20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to complete the Phase 1 Part 3 clinical trial CAMBRIDGE, Mass., June 25, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) (NeuroBo), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the closing of its previously announced sale in a privat ...

$20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to complete the Phase 1 Part 3 clinical trial CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) (NeuroBo), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that it has entered into definitive agreements for the i ...